Puesta al día: Carcinoma paratiroideo

Simple item page
dc.coverageDOI: 10.4067/s0034-98872021000300399
dc.creatorBARBERÁN, MARCELA
dc.creatorCAMPUSANO, CLAUDIA
dc.creatorSALMAN, PATRICIO
dc.creatorTREJO, PAMELA
dc.creatorSILVA-FIGUEROA, ANGÉLICA
dc.creatorRIVERA, SANDRA
dc.creatorFLORENZANO, PABLO
dc.creatorVELASCO, SOLEDAD
dc.creatorILLANES, FRANCISCA
dc.creatorTRINCADO, PATRICIO
dc.creatorCANESSA, JOSÉ
dc.creatorSOLAR, ANTONIETA
dc.creatorMORENO, MARCELA
dc.creatorEUGENIN, DANIELA
dc.creatorJIMÉNEZ, BEATRIZ
dc.creatorARROYO, PATRICIA
dc.date2021
dc.date.accessioned2025-11-18T19:47:59Z
dc.date.available2025-11-18T19:47:59Z
dc.description<p>Parathyroid carcinoma is a rare malignant disease that presents as a sporadic or familial primary hyperparathyroidism (PHP). The latter is associated with some genetic syndromes. It occurs with equal frequency in both sexes, unlike PHP caused by parathyroid adenoma that is more common in women. It should be suspected in cases of severe hypercalcemia, with high parathyroid hormone levels and a palpable cervical mass. Given the difficulty in distinguishing between parathyroid carcinoma and adenoma prior to the surgery, the diagnosis is often made after parathyroidectomy. The only curative treatment is complete surgical resection with oncologic block resection of the primary tumor to ensure free margins. Adjuvant therapies with chemotherapy or radiation therapy do not modify overall or disease-free survival. Recurrences are common and re-operation of resectable recurrent disease is recommended. The palliative treatment of symptomatic hypercalcemia is crucial in persistent or recurrent disease after surgery since morbidity and mortality are more associated with hypercalcemia than with tumor burden.</p>eng
dc.descriptionParathyroid carcinoma is a rare malignant disease that presents as a sporadic or familial primary hyperparathyroidism (PHP). The latter is associated with some genetic syndromes. It occurs with equal frequency in both sexes, unlike PHP caused by parathyroid adenoma that is more common in women. It should be suspected in cases of severe hypercalcemia, with high parathyroid hormone levels and a palpable cervical mass. Given the difficulty in distinguishing between parathyroid carcinoma and adenoma prior to the surgery, the diagnosis is often made after parathyroidectomy. The only curative treatment is complete surgical resection with oncologic block resection of the primary tumor to ensure free margins. Adjuvant therapies with chemotherapy or radiation therapy do not modify overall or disease-free survival. Recurrences are common and re-operation of resectable recurrent disease is recommended. The palliative treatment of symptomatic hypercalcemia is crucial in persistent or recurrent disease after surgery since morbidity and mortality are more associated with hypercalcemia than with tumor burden.spa
dc.identifierhttps://investigadores.uandes.cl/en/publications/1b0e589c-eda9-4ebb-bb96-c59788ab421f
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/55322
dc.languagespa
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.149 (2021) nr.3 p.399-408
dc.subjectDiagnosis
dc.subjectHypercalcemia
dc.subjectHyperparathyroidism
dc.subjectParathyroid Neoplasms
dc.subjectDiagnosis
dc.subjectHypercalcemia
dc.subjectHyperparathyroidism
dc.subjectParathyroid Neoplasms
dc.titlePuesta al día: Carcinoma paratiroideospa
dc.titleAn update on parathyroid carcinomaeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE